Furthermore, the heightened levels of hs-cTnT may be useful in distinguishing cardiac amyloidosis (CA) from HFpEF in light of the fact that, in CA patients, significantly elevated serum hs-cTnT levels have been reported compared to those with cardiac hypertrophy unrelated to CA. This evidence concerns the gene TNNT2 and cardiac hypertrophy.